HK Stock Movement | INNOCARE (09969) Rises Over 3% as NDA Submission for Zorletinib in Pediatric Patients Expected Soon

BRIEF-Innocare Pharma Announces Approval Of Zurletrectinib By China's NMPA

InnoCare Pharma Gets China Nod for Tumor Drug

InnoCare Pharma Ltd - Approval of Zurletrectinib by China's Nmpa

InnoCare Pharma Showcases Over 20 Orelabrutinib Studies Highlighting Efficacy in Lymphoma at ASH 2025

InnoCare Pharma Reports High Remission Rates for Mesutoclax in Relapsed/Refractory Lymphoma and Leukemia Trials

InnoCare Pharma Doses First Patient in Global Phase II Trial of TYK2 Inhibitor Soficitinib for Prurigo Nodularis

InnoCare Announces First Patient Dosed in the Global Phase Ii Clinical Trial of Tyk2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis

InnoCare Pharma Logs Over 34 Million Yuan in Q3 Loss

BRIEF-Innocare Pharma Logs 9M Gross Margin 88.8%

InnoCare Pharma Files Directors List with HKEX

InnoCare Pharma 9M Gross Margin 88.8%

InnoCare Pharma - January to September, Total Operating Revenue of RMB1.12 Bln

Innocare Pharma Limited (688428.SH) Reports Q3 Results with Net Loss of 64.41 Million Yuan

InnoCare Pharma Board to Review Third Quarterly Results

InnoCare Pharma Doses First Patient in Clinical Trial of Novel B7-H3 ADC ICP-B794

InnoCare Announces First Patient Dosed in Clinical Trial of Novel ADC Icp-B794 in China

InnoCare Pharma Reports Promising Results for Zurletrectinib in Pediatric Solid Tumors

INNOCARE (09969) Repurchases 800,000 Shares for HK$11.768 Million on October 10

BUZZ-Zenas BioPharma hits record high as brokerages raise PT